Sodium-glucose co-transporter-2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes: systematic review and meta-analysis

Sodium-glucose co-transporter-2 inhibitors in patients with chronic kidney disease with or without type 2 diabetes: systematic review and meta-analysis

Objective To examine cardiovascular and kidney benefits and harms of sodium-glucose co-transporter-2 (SGLT-2) inhibitors stratified by risk in adults with chronic kidney disease regardless of diabetes status.Design Systematic review and meta-analysis.Data sources Ovid Medline, Embase, and Cochrane C...

Full description

Saved in:

Bibliographic Details
Main Authors:	Gordon Guyatt, Arnav Agarwal, Thomas Agoritsas, Haoming Tian, Sheyu Li, Chang Xu, Ping Fu, Qingyang Shi, Xiaoxi Zeng, Per Olav Vandvik, Xinyu Zou, Yunhe Mao, Qinbo Yang, Xianghang Luo, Belen Ponte
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-08-01
Series:	BMJ Medicine
Online Access:	https://bmjmedicine.bmj.com/content/3/1/e001009.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinicians’ experience with infographic summaries from the BMJ Rapid Recommendations: a qualitative user-testing study among residents and interns at a large teaching hospital in Switzerland
by: Thomas Agoritsas, et al.
Published: (2025-02-01)

Assessment of the Utilization of Sodium–Glucose Cotransporter-2 Inhibitors in Patients Without Diabetes
by: Takuma Koinuma, et al.
Published: (2024-12-01)

Advances in sodium-glucose transporter protein 2 inhibitors and tumors
by: Jiaqi Wang, et al.
Published: (2025-02-01)

Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
by: Muhammad Shahzeb Khan, et al.
Published: (2019-11-01)

Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors
by: Riber Fabián Donoso Noroña, et al.
Published: (2024-09-01)

Sodium‐glucose cotransporter‐2 inhibitors in heart failure: an updated meta‐analysis
by: Yang Cao, et al.
Published: (2022-06-01)

Uninephrectomy and sodium‐glucose cotransporter 2 inhibitor administration delay the onset of hyperglycemia
by: Yuri Sakai Ishizaki, et al.
Published: (2024-11-01)

Sodium-Glucose Transport Protein 2 Inhibitors Association with Euglycemic Diabetic Ketoacidosis
by: Caroline Wojtas, et al.
Published: (2023-01-01)

Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update
by: Nicia I. Profili, et al.
Published: (2024-10-01)

Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
by: Kyoung Hwa Ha, et al.
Published: (2025-02-01)

Impact of Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Exercise‐Induced Pulmonary Hypertension
by: Taijyu Satoh, et al.
Published: (2024-10-01)

Unmasking of normocalcemic primary hyperparathyroidism after sodium-glucose cotransporter-2 inhibitor initiation
by: Christodoulos Dolapsakis, et al.
Published: (2025-01-01)

Sodium‐Glucose Cotransporter 2 Inhibitors for Mesenchymal–Epithelial Transition Inhibitor‐Induced Edema
by: Takuya Oyakawa, et al.
Published: (2025-01-01)

Diabetic Ketoacidosis as an Effect of Sodium-Glucose Cotransporter 2 Inhibitor: Real World Insights
by: Han-Sang Baek, et al.
Published: (2024-11-01)

The influence of the pharmacodynamic properties of drugs on indications for their use: Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors)
by: Denda Nikola I., et al.
Published: (2024-01-01)

Effect of sodium glucose cotransporter-2 inhibitors (SGLT-2is) on the clinical outcomes of patients with diabetic atrial fibrillation
by: Selim Aydemir, et al.
Published: (2024-12-01)

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
by: Gilda M. Portalatin, et al.
Published: (2025-01-01)

Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes
by: Mazhar Hussain, et al.
Published: (2021-01-01)

Haemodynamic Effects of Sodium–Glucose Cotransporter 2 Inhibitor Treatment in Chronic Heart Failure Patients
by: C Noah Nilsson, et al.
Published: (2024-09-01)

Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
by: Giuseppe Rosano, et al.
Published: (2020-11-01)

Treatment of Heart Failure with Sodium-Glucose Cotransporter 2 Inhibitors and Other Anti-diabetic Drugs
by: Thomas A Zelniker, et al.
Published: (2019-01-01)

Focusing on Sodium Glucose Cotransporter-2 and the Sympathetic Nervous System: Potential Impact in Diabetic Retinopathy
by: Lakshini Y. Herat, et al.
Published: (2018-01-01)

The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure
by: Anastasia D. Egorova, et al.
Published: (2022-06-01)

The role of sodium – glucose cotransporter-2 inhibitors in the treatment of different phenotypes of chronic heart failure
by: M. Yu. Kolesnyk, et al.
Published: (2024-03-01)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
by: Kris Aubrey-Bassler, et al.
Published: (2019-02-01)

Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD)
by: Min-Jia Cao, et al.
Published: (2025-01-01)

Effect of sodium-glucose Co-transporter 2 inhibitors on MCP-1 and uromodulin levels in patients with type 2 diabetes mellitus
by: Mani Pathak, et al.
Published: (2025-01-01)

The Promising Potency of Sodium–Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients
by: Yibin Zhang, et al.
Published: (2024-12-01)

Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes in Patients with Acute Coronary Syndrome and Type 2 Diabetes
by: Xie H, et al.
Published: (2024-11-01)

Single Center Experience With Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Kidney Transplant Recipients With Diabetes
by: Albi Angjeli, et al.
Published: (2024-11-01)

Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease
by: Supattra Hunsuwan, et al.
Published: (2025-01-01)

Feasibility and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Heart Failure after the Fontan Procedure
by: Jun Muneuchi, et al.
Published: (2022-01-01)

Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy
by: Eun Hyung Cho, et al.
Published: (2018-01-01)

Effects of Sodium–Glucose Co-Transporter 2 Inhibitors on Serum Chloride Concentrations in Patients with Heart Failure
by: Ivana Jurin, et al.
Published: (2024-11-01)

Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care
by: Dong-Dong Wang, et al.
Published: (2022-01-01)

Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
by: Juan Tamargo
Published: (2019-01-01)

Incidental changes in hemoglobin levels in patients with myelofibrosis receiving treatment with sodium-glucose co-transporter-2 inhibitors
by: Fnu Aperna, et al.
Published: (2024-11-01)

Sodium-glucose cotransporter 2 inhibition in patients with liver cirrhosis and diabetes: a possible role in ascites control?
by: Aurelio Seidita, et al.
Published: (2024-11-01)

Absorption Efficiency Assessment and Uncertainty Measurement of the Sodium Arsenite Method for Ambient NO2 Determination
by: Rishu Agarwal, et al.
Published: (2020-12-01)

Corrigendum to: Sodium–glucose Cotransporter 2 Inhibitors in Heart Failure: Potential Mechanisms of Action, Adverse Effects and Future Developments
by: Juan Tamargo
Published: (2019-12-01)